My watch list
my.bionity.com  

my.bionity.com

With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Volociximab



Volociximab?
Therapeutic monoclonal antibody
Source Chimeric
Target a5b1 integrin
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.

v • d • e
Chimeric monoclonal antibodies
Cancer immunotherapyCetuximab, Rituximab
OtherAbciximab, Basiliximab, Bavituximab, Clenoliximab, Ecromeximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Pagibaximab, Teneliximab, Vapaliximab, Volociximab
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Volociximab". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE